The Life Raft Group is committed to enhancing the survival and quality of life for people living with Gastrointestinal Stromal Tumor (GIST), and other rare diseases, through patient-powered research, education and empowerment, and global advocacy efforts.
Other Programs Supported by The Life Raft Group:
Real World Evidence In Action
Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRG’s approach to GIST research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.
RECENT LRG DATA
Update your Patient Registry Info.
Join The Life Raft Group.
Current GIST Clinical Trials.
Search the GIST Specialist Database.
HELP US SAVE LIVES
The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our GIST patient registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.
News
New Horizons – International Focus on the Power of Real World Data to Enhance Advocacy Efforts
International advocates meet in Wayne, NJ, at the annual New Horizons GIST Conference to discuss scientific updates, regional issues, and unmet needs for the global GIST community in May 2019.
The First GIST DO IT Walk NJ – Held in Loving Memory of Ted Wolf
On May 4, 2019, The Life Raft Group held its first GIST DO IT Walk in New Jersey, at Verona Park. Despite the drizzle, over 50 people were in attendance and over $18K was raised for #GISTresearch.
International Collaborations – Salud con Datos 2019
International collaborations accelerate patient advocacy and affect policy changes and treatment protocols On May 7th, representatives from Colombia, Chile, [...]
Fifth Annual Water of Life Fundraiser 2019
Dr. Matthew Lurin’s Fifth Annual Water of Life Whisky fundraiser was held on May 16th at the Manhattan Center [...]
Update on a New Clinical Trial Offered to Eligible GIST Patients
The INTRIGUE study is a Phase 3 clinical trial testing the investigational drug ripretinib (DCC-2618) for patients living with GIST that are no longer on imatinib due to progression or intolerance.
On the Speaking Circuit with The LRG
Norman Scherzer was invited to speak at three prestigious events this spring; participating in a roundtable discussion, presenting a cancer survival [...]
GIST Day of Learning – GDOL Tampa
The Life Raft Group held a GIST Day of Learning (GDOL) in Tampa, at Moffitt Cancer Center, on May 16th, 2019. [...]
One Voice Against Cancer (OVAC) Advocates for Cancer Patients
OVAC is a coalition of over 50 nonprofit cancer organizations that advocate on behalf of cancer patients to deliver a unified [...]





























